# US 10,870,680 B2 · Methods of reducing neuronal injury or toxicity in epilepsy, Alzheimer's disease or Parkinson's disease using a scorpion venom heat-resistant synthetic peptide (SVHRSP)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,870,680 B2
- Document ID: US10870680B2
- Status: Granted
- Kind: B2
- Application number: 16/573,495
- Filed: 2019-09-17
- Published: 2020-01-02
- Granted: 2020-12-22
- Earliest claimed: 2016-08-08
- Assignees: Dalian Medical University
- Applicants: Dalian Medical University
- Inventors: Jie Zhao; Shao Li; Wanqin Zhang
- Web page: https://patentgrep.com/patent/US10870680B2

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 14/43522: {from scorpions}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 38/02: Peptides of undefined number of amino acids; Derivatives thereof
- A61K 47/6415: {Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins}
- A61K 47/6817: {Toxins}
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 14/43504: {from invertebrates}
- C07K 14/43518: {from spiders}
- C12N 2310/3513: Protein; Peptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A scorpion venom heat-resistant synthetic peptide (SVHRSP) contains an amino acid sequence of SEQ ID NO 1. One or more amino acids the amino acid sequence can be substituted or deleted. A pharmaceutical composition that contains the SVHRSP has numerous applications. The pharmaceutical composition can be used to protect neuronal cell against amyloid beta-induced toxic effects, or to inhibit the sodium channel current of a hippocampal neuronal cell, or to protect a neuronal cell against NMDA-induced injury. It may also promote the formation of a pluripotent neural stem cell from a type II astrocyte, or treats a subject, such as a human, having epilepsy, Alzheimer's disease, or Parkinson's disease.

## Claims

### Claim 1

A method of alleviating symptoms of a neurological disease associated with amyloid beta-induced toxic effect, oxidative stress, or NMDA-induced injury, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises a scorpion venom heat-resistant synthetic peptide (SVHRSP) consisting of the amino acid sequence of SEQ ID NO 1 and the neurological disease is epilepsy, Alzheimer's disease, or Parkinson's disease.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the neurological disease is epilepsy.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the subject is a human.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the neurological disease is Alzheimer's disease.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the subject is a human.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the neurological disease is Parkinson's disease.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the subject is a human.

### Claim 8

A method of protecting a neuronal cell against an adverse effect, the method comprising contacting the neuronal cell with an effective amount of a pharmaceutical composition in vitro, wherein the pharmaceutical composition comprises a scorpion venom heat-resistant synthetic peptide (SVHRSP) consisting of the amino acid sequence of SEQ ID NO 1 and the adverse effect is amyloid beta-induced toxic effect, oxidative stress, or NMDA-induced injury.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the adverse effect is amyloid beta-induced toxic effects.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the adverse effect is oxidative stress.

### Claim 11 (depends on 8)

The method according to claim 8, wherein the adverse effect is NMDA-induced injury.

### Claim 12

A method of inhibiting the sodium channel current of a hippocampal neuronal cell, the method comprising contacting the hippocampal neuronal cell with an effective amount of a pharmaceutical composition in vitro, wherein the pharmaceutical composition comprises a scorpion venom heat-resistant synthetic peptide (SVHRSP) consisting of the amino acid sequence of SEQ ID NO 1.